| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding | |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | Entrez:596 MIM:151430 HGNC:HGNC:990 Ensembl:ENSG00000171791 AllianceGenome:HGNC:990 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | BCL2 apoptosis regulator | |||||
| GTO ID | GTC1290 |
| Trial ID | NCT00636545 |
| Disease | Solid Tumor |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors |
| Year | 2007 |
| Country | United States |
| Company sponsor | Genta Incorporated |
| Other ID(s) | GPK109 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||